Valuation: BriaCell Therapeutics Corp.

Market Cap 29.89M 25.82M 24.26M 22.06M 41.48M 2.86B 42.16M 284M 111M 1.43B 112M 110M 4.76B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 12.02M 10.39M 9.76M 8.88M 16.69M 1.15B 16.96M 114M 44.71M 576M 45.15M 44.17M 1.91B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
1 day-1.46%
1 week-6.71%
Current month-1.87%
1 month-9.39%
3 months-14.77%
6 months-14.00%
Current year-51.73%
1 week 4.67
Extreme 4.67
4.91
1 month 4.61
Extreme 4.61
5.45
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
20.4
3 years 3.68
Extreme 3.68
1,543.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 31/10/2016
Director of Finance/CFO 54 31/01/2016
Chief Tech/Sci/R&D Officer 65 15/02/2022
Director TitleAgeSince
Director/Board Member 70 31/10/2016
Chairman 41 23/04/2019
Director/Board Member 74 06/03/2019
Date Insider Type Main position Quantity % Market Cap.
07/07/26 Tax

Director

45,000 0.5173%
07/07/26 Tax

Director

15,000 0.1724%
07/07/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%-6.71%-52.22%-99.67% 29.95M
-1.90%+11.59%+62.29%+102.60% 71.56B
-3.21%-4.32%+31.19%+59.75% 54.43B
-2.05%-5.61%-3.14%+454.89% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
+1.05%-0.62%-17.40%-13.36% 23.14B
+0.10%+1.40%+38.98%-20.04% 18.65B
+3.81%+20.97%+263.48%+552.47% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+1.24%-5.23%+33.19%+138.21% 12.54B
Average -0.46%+1.65%+42.29%+179.40% 26.65B
Weighted average by Cap. -1.13%+0.48%+49.35%+166.79%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.14M -3.89M -3.54M -6.65M -458M -6.76M -45.57M -17.82M -229M -17.99M -17.6M -762M -26.31M -22.73M -21.35M -19.42M -36.51M -2.52B -37.12M -250M -97.83M -1.26B -98.79M -96.64M -4.19B
Net Debt -862K -745K -700K -636K -1.2M -82.43M -1.22M -8.2M -3.21M -41.28M -3.24M -3.17M -137M -17.87M -15.43M -14.5M -13.19M -24.79M -1.71B -25.2M -170M -66.43M -856M -67.08M -65.62M -2.84B
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
14/08/26 CA$4.730 -1.46% 1,081
13/08/26 CA$4.800 +1.27% 1,109
12/08/26 CA$4.740 -0.84% 131
11/08/26 CA$4.780 +1.27% 1,425
10/08/26 CA$4.720 -6.90% 5,273

Quarterly revenue - Rate of surprise